EV Therapeutics is developing novel therapies to induce an anti-tumor immune response in advanced stage metastatic colorectal cancers. Our technology is based on our proprietary modified extracellular vesicles (mEVs) that significantly enhance tumor antigen-specific T cell infiltration into the tumor microenvironment and synergizes with current immune checkpoint blockade therapies. Mechanistically, our therapeutic platform activates tumor-specific T cell costimulation. Our extensive pre-clinical data show that treatment with mEVs significantly improves survival in late-stage disease models. Our findings potentially translate to a significant survival advantage for human colorectal cancer patients with advanced disease. Our modified extracellular vesicles-based therapy also controls the minimal residual disease that can prevent cancer recurrence functioning as a cancer vaccine. We are seeking out-licensing, co-development, and partnering opportunities.
Company Details
- Address
- San Francisco, Ca 94002, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.evtherapeutics.com
- HQ
- San Francisco, CA
Ev Therapeutics Questions
Ev Therapeutics's website is http://www.evtherapeutics.com
Ev Therapeutics's LinkedIn profile is https://www.linkedin.com/company/ev-therapeutics
Ev Therapeutics's industry is
Biotechnology Research
Ev Therapeutics's top competitors are
Novoron Bioscience,
Aegle Therapeutics,
Trestle Biotherapeutics,
Ilias Biologics Inc.,
Origami Therapeutics, Inc.,
Aluda Pharmaceuticals, Inc.,
Palm Therapeutics,
Endure Biotherapeutics,
Abilita Therapeutics, Inc.,
Capricor Therapeutics, Inc..
Ev Therapeutics's categories are Biotechnology Research
